## Walter J Paulus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11656046/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Novel Paradigm for Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2013, 62, 263-271.	2.8	2,555
2	How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal, 2007, 28, 2539-2550.	2.2	2,302
3	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	2.2	944
4	Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European Heart Journal, 2011, 32, 670-679.	2.2	911
5	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation, 2016, 134, 73-90.	1.6	747
6	Aortic stenosis. Lancet, The, 2009, 373, 956-966.	13.7	668
7	Diastolic Stiffness of the Failing Diabetic Heart. Circulation, 2008, 117, 43-51.	1.6	621
8	Myocardial Structure and Function Differ in Systolic and Diastolic Heart Failure. Circulation, 2006, 113, 1966-1973.	1.6	558
9	Cardiomyocyte Stiffness in Diastolic Heart Failure. Circulation, 2005, 111, 774-781.	1.6	466
10	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	7.1	434
11	What Mechanisms Underlie Diastolic Dysfunction in Heart Failure?. Circulation Research, 2004, 94, 1533-1542.	4.5	425
12	Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction. Circulation, 2012, 126, 830-839.	1.6	418
13	Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. European Heart Journal, 2015, 36, 1718-1727.	2.2	392
14	Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 312-324.	4.1	390
15	Ultrasound and Microbubble-Targeted Delivery of Macromolecules Is Regulated by Induction of Endocytosis and Pore Formation. Circulation Research, 2009, 104, 679-687.	4.5	388
16	B-Type Natriuretic Peptide and Prognosis in Heart Failure Patients With Preserved and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2013, 61, 1498-1506.	2.8	352
17	Hypophosphorylation of the Stiff N2B Titin Isoform Raises Cardiomyocyte Resting Tension in Failing Human Myocardium. Circulation Research, 2009, 104, 780-786.	4.5	318
18	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal, 2014, 35, 2797-2815.	2.2	304

#	Article	IF	CITATIONS
19	Right Ventricular Diastolic Impairment in Patients With Pulmonary Arterial Hypertension. Circulation, 2013, 128, 2016-2025.	1.6	294
20	Effects of tDCS on motor learning and memory formation: A consensus and critical position paper. Clinical Neurophysiology, 2017, 128, 589-603.	1.5	275
21	Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature, 2015, 519, 472-476.	27.8	274
22	Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. European Journal of Heart Failure, 2016, 18, 588-598.	7.1	242
23	Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model. Circulation: Heart Failure, 2013, 6, 1239-1249.	3.9	241
24	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	7.1	239
25	Treatment of Heart Failure With Normal Ejection Fraction. Journal of the American College of Cardiology, 2010, 55, 526-537.	2.8	238
26	Myocardial Contractile Response to Nitric Oxide and cGMP. Circulation, 1996, 93, 1223-1229.	1.6	230
27	Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus. Circulation, 2009, 119, 2069-2077.	1.6	210
28	Peripartum Cardiomyopathy as a Part of Familial Dilated Cardiomyopathy. Circulation, 2010, 121, 2169-2175.	1.6	207
29	Transstenotic coronary pressure gradient measurement in humans: In vitro and in vivo evaluation of a new pressure monitoring angioplasty guide wire. Journal of the American College of Cardiology, 1993, 22, 119-126.	2.8	206
30	Diabetes Mellitus Worsens Diastolic Left Ventricular Dysfunction in Aortic Stenosis Through Altered Myocardial Structure and Cardiomyocyte Stiffness. Circulation, 2011, 124, 1151-1159.	1.6	196
31	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 391-412.	7.1	193
32	Bisoprolol Delays Progression Towards Right Heart Failure in Experimental Pulmonary Hypertension. Circulation: Heart Failure, 2012, 5, 97-105.	3.9	184
33	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	2.2	171
34	Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species. Cardiovascular Research, 2007, 75, 770-781.	3.8	150
35	Sarcomeric dysfunction in heart failure. Cardiovascular Research, 2007, 77, 649-658.	3.8	150
36	Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. Cardiovascular Research, 2018, 114, 954-964.	3.8	148

#	Article	IF	CITATIONS
37	Endomyocardial Nitric Oxide Synthase and Left Ventricular Preload Reserve in Dilated Cardiomyopathy. Circulation, 1999, 99, 3009-3016.	1.6	146
38	Paracrine Coronary Endothelial Control of Left Ventricular Function in Humans. Circulation, 1995, 92, 2119-2126.	1.6	142
39	Right Ventricular Diastolic Dysfunction and the Acute Effects of Sildenafil in Pulmonary Hypertension Patients. Chest, 2007, 132, 11-17.	0.8	138
40	From Systemic Inflammation to Myocardial Fibrosis. Circulation Research, 2021, 128, 1451-1467.	4.5	132
41	The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2013, 2, e000536.	3.7	131
42	Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and RestoredÂby Empagliflozin. JACC Basic To Translational Science, 2019, 4, 575-591.	4.1	125
43	Doppler Echocardiography Yields Dubious Estimates of Left Ventricular Diastolic Pressures. Circulation, 2009, 120, 810-820.	1.6	111
44	Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1038-H1047.	3.2	105
45	Effect of early-onset preeclampsia on cardiovascular risk in the fifth decade of life. American Journal of Obstetrics and Gynecology, 2017, 216, 523.e1-523.e7.	1.3	100
46	Comparison of the effects of nitroprusside and nifedipine on diastolic properties in patients with hypertrophic cardiomyopathy: Altered left ventricular loading or improved muscle inactivation?. Journal of the American College of Cardiology, 1983, 2, 879-886.	2.8	99
47	Biomarkers of heart failure with normal ejection fraction: a systematic review. European Journal of Heart Failure, 2013, 15, 1350-1362.	7.1	97
48	Molecular and Cellular Basis for Diastolic Dysfunction. Current Heart Failure Reports, 2012, 9, 293-302.	3.3	96
49	Improved Diastolic Function and Systolic Performance in Hypertrophic Cardiomyopathy after Nifedipine. New England Journal of Medicine, 1980, 303, 801-803.	27.0	92
50	Left-Ventricular Remodeling After Myocardial Infarction Is Associated with a Cardiomyocyte-Specific Hypothyroid Condition. Endocrinology, 2011, 152, 669-679.	2.8	92
51	Distinct Myocardial Targets for DiabetesÂTherapy in Heart Failure With Preserved orÂReduced Ejection Fraction. JACC: Heart Failure, 2018, 6, 1-7.	4.1	90
52	SIH—a novel lipophilic iron chelator—protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. Journal of Molecular and Cellular Cardiology, 2005, 39, 345-354.	1.9	85
53	Quantitative analysis of myofilament protein phosphorylation in small cardiac biopsies. Proteomics - Clinical Applications, 2007, 1, 1285-1290.	1.6	80
54	Circulating ACE2 activity correlates with cardiovascular disease development. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2016, 17, 147032031666843.	1.7	80

#	Article	IF	CITATIONS
55	Heart failure and cognitive function in the general population: the Hoorn Study. European Journal of Heart Failure, 2011, 13, 1362-1369.	7.1	78
56	Functional effects of protein kinase C-mediated myofilament phosphorylation in human myocardium. Cardiovascular Research, 2006, 69, 876-887.	3.8	71
57	Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H1752-H1759.	3.2	70
58	Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. Cardiovascular Research, 2014, 104, 423-431.	3.8	70
59	Myocardial stress and hypertrophy: a complex interface between biophysics and cardiac remodeling. Journal of Clinical Investigation, 2013, 123, 3701-3703.	8.2	67
60	Nitric oxide's role in the heart: control of beating or breathing?. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H8-H13.	3.2	66
61	Distinct Endothelial Cell Responses in the Heart and Kidney Microvasculature Characterize the Progression of Heart Failure With Preserved Ejection Fraction in the Obese ZSF1 Rat With Cardiorenal Metabolic Syndrome. Circulation: Heart Failure, 2016, 9, e002760.	3.9	62
62	Circulating white blood cells and platelets amplify oxidative stress in heart failure. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 811-820.	3.3	61
63	How are cytokines activated in heart failure?. European Journal of Heart Failure, 1999, 1, 309-312.	7.1	59
64	The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. European Journal of Heart Failure, 2010, 12, 1274-1281.	7.1	56
65	The role of nitric oxide in the failing heart. , 2001, 6, 105-118.		54
66	Effects of Aging on Left Atrioventricular Coupling and Left Ventricular Filling Assessed Using Cardiac Magnetic Resonance Imaging in Healthy Subjects. American Journal of Cardiology, 2007, 100, 122-127.	1.6	54
67	Transcriptional and Posttranslational Modifications of Titin. Circulation Research, 2009, 104, 12-14.	4.5	54
68	Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload. Basic Research in Cardiology, 2011, 106, 801-814.	5.9	54
69	NOX5 Expression Is Increased in Intramyocardial Blood Vessels and Cardiomyocytes after Acute Myocardial Infarction in Humans. American Journal of Pathology, 2012, 180, 2222-2229.	3.8	53
70	Advantages of deformation indices over systolic velocities in assessment of longitudinal systolic function in patients with heart failure and normal ejection fraction. European Journal of Heart Failure, 2011, 13, 292-302.	7.1	52
71	Does Myocardial Fibrosis Hinder Contractile Function and Perfusion in Idiopathic Dilated Cardiomyopathy? PET and MR Imaging Study. Radiology, 2006, 240, 380-388.	7.3	51
72	Myofilament Degradation and Dysfunction of Human Cardiomyocytes in Fabry Disease. American Journal of Pathology, 2008, 172, 1482-1490.	3.8	51

#	Article	IF	CITATIONS
73	Unfolding Discoveries in Heart Failure. New England Journal of Medicine, 2020, 382, 679-682.	27.0	51
74	Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. European Heart Journal, 2009, 30, 1863-1872.	2.2	50
75	Intravenous clusterin administration reduces myocardial infarct size in rats. European Journal of Clinical Investigation, 2010, 40, 893-902.	3.4	50
76	Shared biomarkers between female diastolic heart failure and preâ€eclampsia: a systematic review and metaâ€analysis. ESC Heart Failure, 2017, 4, 88-98.	3.1	47
77	Molecular determinants of heart failure with normal left ventricular ejection fraction. Pharmacological Reports, 2009, 61, 139-145.	3.3	46
78	The influence of endothelium-derived nitric oxide on myocardial contractile function. International Journal of Cardiology, 1995, 50, 225-231.	1.7	44
79	The cardiac endothelium: Cardioactive mediators. Progress in Cardiovascular Diseases, 1996, 39, 263-284.	3.1	44
80	Myocardial Titin and Collagen in Cardiac Diastolic Dysfunction. Circulation, 2013, 128, 5-8.	1.6	43
81	Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1770-1780.	1.6	43
82	Dobutamine Enhances Cardiodepressant Effects of Receptor-Mediated Coronary Endothelial Stimulation. Circulation, 1997, 95, 90-96.	1.6	41
83	More severe cellular phenotype in human idiopathic dilated cardiomyopathy compared to ischemic heart disease. Journal of Muscle Research and Cell Motility, 2010, 31, 289-301.	2.0	38
84	Diastolic function of the nonfilling human left ventricle. Journal of the American College of Cardiology, 1992, 20, 1524-1532.	2.8	37
85	The failing diabetic heart: Focus on diastolic left ventricular dysfunction. Current Diabetes Reports, 2009, 9, 79-86.	4.2	36
86	H <sub>2</sub> FPEF Score. Circulation, 2018, 138, 871-873.	1.6	36
87	Rationale and application of coronary transstenotic pressure gradient measurements. Catheterization and Cardiovascular Diagnosis, 1994, 33, 250-261.	0.3	35
88	Early-onset preeclampsia predisposes to preclinical diastolic left ventricular dysfunction in the fifth decade of life: An observational study. PLoS ONE, 2018, 13, e0198908.	2.5	35
89	Left Ventricular Contractile Effects of Inducible Nitric Oxide Synthase in the Human Allograft. Circulation, 1997, 96, 3436-3442.	1.6	34
90	Nitric Oxide and Cardiac Contractility in Human Heart Failure. Circulation, 2001, 104, 2260-2262.	1.6	33

Walter J Paulus

#	Article	IF	CITATIONS
91	Matrix, Cytoskeleton, or Myofilaments: Which One to Blame for Diastolic Left Ventricular Dysfunction?. Progress in Cardiovascular Diseases, 2005, 47, 276-284.	3.1	32
92	MicroRNA 214 Is a Potential Regulator of Thyroid Hormone Levels in the Mouse Heart Following Myocardial Infarction, by Targeting the Thyroid-Hormone-Inactivating Enzyme Deiodinase Type III. Frontiers in Endocrinology, 2016, 7, 22.	3.5	32
93	Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarction. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 753-763.	4.9	31
94	Ventricular myocarditis coincides with atrial myocarditis in patients. Cardiovascular Pathology, 2016, 25, 141-148.	1.6	31
95	Increased local delivery of antagomir therapeutics to the rodent myocardium using ultrasound and microbubbles. Journal of Controlled Release, 2016, 222, 18-31.	9.9	30
96	Contractile arrest reveals calcium-dependent stimulation of SERCA2a mRNA expression in cultured ventricular cardiomyocytes. Cardiovascular Research, 2004, 63, 537-544.	3.8	29
97	From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. Heart, 2016, 102, 320-330.	2.9	29
98	Investigating a biomarkerâ€driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum Câ€ŧerminal propeptide of procollagen type I (DROPâ€PIP trial). European Journal of Heart Failure, 2018, 20, 460-470.	7.1	29
99	Atrial Fibrillation Coincides with the Advanced Glycation End Product NÎμ-(Carboxymethyl)Lysine in the Atrium. American Journal of Pathology, 2015, 185, 2096-2104.	3.8	28
100	Beneficial effects of nitric oxide on cardiac diastolic function: 'the flip side of the coin'. Heart Failure Reviews, 2000, 5, 337-344.	3.9	27
101	Prospective Associations of B-Type Natriuretic Peptide With Markers of Left Ventricular Function in Individuals With and Without Type 2 Diabetes. Diabetes Care, 2012, 35, 2510-2514.	8.6	27
102	Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model. Journal of Molecular and Cellular Cardiology, 2019, 137, 119-131.	1.9	27
103	Myocardial contractile effects of nitric oxide. Heart Failure Reviews, 2002, 7, 371-383.	3.9	26
104	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers, 2020, 25, 201-211.	1.9	26
105	Slightly elevated Bâ€ŧype natriuretic peptide levels in a nonâ€heart failure range indicate a worse left ventricular diastolic function in individuals with, as compared with individuals without, type 2 diabetes: the Hoorn Study. European Journal of Heart Failure, 2010, 12, 958-965.	7.1	24
106	Do Existing Definitions Identify Subgroup Phenotypes or Reflect the Natural History of Heart Failure With Preserved Ejection Fraction?. Circulation, 2019, 140, 366-369.	1.6	24
107	H9c2 cardiomyoblasts produce thyroid hormone. American Journal of Physiology - Cell Physiology, 2008, 294, C1227-C1233.	4.6	22
108	RhoA-ROCK signaling is involved in contraction-mediated inhibition of SERCA2a expression in cardiomyocytes. Pflugers Archiv European Journal of Physiology, 2009, 458, 785-793.	2.8	22

#	Article	IF	CITATIONS
109	Endomyocardial nitric oxide synthase and the hemodynamic phenotypes of human dilated cardiomyopathy and of athlete's heart. Cardiovascular Research, 2002, 55, 270-278.	3.8	21
110	Independent Associations of Glucose Status and Arterial Stiffness With Left Ventricular Diastolic Dysfunction. Diabetes Care, 2012, 35, 1258-1264.	8.6	21
111	Orifice variability of the stenotic aortic valve: Evaluation before and after balloon aortic valvuloplasty. Journal of the American College of Cardiology, 1991, 17, 1263-1269.	2.8	20
112	α-B Crystallin Reverses High Diastolic Stiffness of Failing Human Cardiomyocytes. Circulation: Heart Failure, 2017, 10, e003626.	3.9	20
113	The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review. Expert Opinion on Biological Therapy, 2018, 18, 585-594.	3.1	20
114	A Novel Electrocardiographic Index for the Diagnosis of Diastolic Dysfunction. PLoS ONE, 2013, 8, e79152.	2.5	20
115	Early NADPH oxidase-2 activation is crucial in phenylephrine-induced hypertrophy of H9c2 cells. Cellular Signalling, 2014, 26, 1818-1824.	3.6	19
116	Endothelial control of vascular and myocardial function in heart failure. Cardiovascular Drugs and Therapy, 1994, 8, 437-446.	2.6	18
117	Novel strategies in diastolic heart failure. Heart, 2010, 96, 1147-1153.	2.9	18
118	Ultrasound and Microbubble-Induced Local Delivery of MicroRNA-Based Therapeutics. Ultrasound in Medicine and Biology, 2015, 41, 163-176.	1.5	18
119	Stretch-induced compliance: a novel adaptive biological mechanism following acute cardiac load. Cardiovascular Research, 2018, 114, 656-667.	3.8	18
120	NOX2, p22 <sup>phox</sup> and p47 <sup>phox</sup> are Targeted to the Nuclear Pore Complex in Ischemic Cardiomyocytes Colocalizing with Local Reactive Oxygen Species. Cellular Physiology and Biochemistry, 2011, 27, 471-478.	1.6	17
121	Pathophysiological rationale and diagnostic targets for diastolic stress testing. Heart, 2015, 101, 1355-1360.	2.9	17
122	Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e005596.	3.9	17
123	Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. European Journal of Heart Failure, 2020, 22, 1586-1597.	7.1	16
124	Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIAâ€HFpEF trial. ESC Heart Failure, 2020, 7, 4478-4487.	3.1	15
125	Diagnostic value of echocardiographic markers for diastolic dysfunction and heart failure with preserved ejection fraction. Heart Failure Reviews, 2022, 27, 207-218.	3.9	15
126	Nitric oxide: the missing lusitrope in failing myocardium. European Heart Journal, 2008, 29, 2453-2455.	2.2	14

#	Article	IF	CITATIONS
127	Polishing the diastolic dysfunction measurement stick. European Journal of Echocardiography, 2008, 9, 575-577.	2.3	14
128	Diastolic and systolic heart failure: Different stages or distinct phenotypes of the heart failure syndrome?. Current Heart Failure Reports, 2009, 6, 281-286.	3.3	14
129	Heart failure with preserved ejection fraction: a nephrologist-directed primer. Heart Failure Reviews, 2017, 22, 765-773.	3.9	14
130	Myocardial Contractile Effects of l-Arginine in the Human Allograft. Journal of the American College of Cardiology, 1997, 29, 1332-1338.	2.8	13
131	The future diagnosis of heart failure with normal ejection fraction: less imaging, more biomarkers?. European Journal of Heart Failure, 2011, 13, 1043-1045.	7.1	13
132	Myocardial fibrosis blunts nitric oxide synthase-related preload reserve in human dilated cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H10-H16.	3.2	12
133	The Basement Membrane of Intramyocardial Capillaries Is Thickened in Patients with Acute Myocardial Infarction. Journal of Vascular Research, 2010, 47, 54-60.	1.4	12
134	Sex differences in circulating proteins in heart failure with preserved ejection fraction. Biology of Sex Differences, 2020, 11, 47.	4.1	12
135	Paracrine coronary endothelial modulation of diastolic left ventricular function in man: Implications for diastolic heart failure. Journal of Cardiac Failure, 1996, 2, S155-S164.	1.7	11
136	Low-grade inflammation and endothelial dysfunction explain the association between retinopathy and left ventricular ejection fraction in men: an 8-year follow-up of the Hoorn Study. Journal of Diabetes and Its Complications, 2014, 28, 819-823.	2.3	11
137	Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus. European Journal of Heart Failure, 2018, 20, 1649-1652.	7.1	11
138	Cellular Mechanisms for Diastolic Dysfunction in the Human Heart. Current Pharmaceutical Biotechnology, 2012, 13, 2532-2538.	1.6	11
139	Iconoclasts topple adaptive myocardial hypertrophy in aortic stenosisThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology European Heart Journal, 2005, 26, 1697-1699.	2.2	10
140	Myocardial infarction induces atrial inflammation that can be prevented by C1-esterase inhibitor. Journal of Clinical Pathology, 2016, 69, 1093-1099.	2.0	10
141	Microvascular Paradigm in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	3.9	9
142	Myocardial Contractile Effects of Nitric Oxide. , 2004, , 33-45.		8
143	Treatment of Heart Failure With Normal Ejection Fraction. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 26-34.	0.9	8
144	Phosphodiesteraseâ€5 inhibition in heart failure with preserved ejection fraction: trading therapy for prevention. European Journal of Heart Failure, 2017, 19, 337-339.	7.1	8

Walter J Paulus

#	Article	IF	CITATIONS
145	Phenotypic Persistence in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e005956.	3.9	8
146	Cellular mechanisms for diastolic dysfunction in the human heart. Current Pharmaceutical Biotechnology, 2012, 13, 2532-8.	1.6	8
147	The dialogue between diabetes and diastole. European Journal of Heart Failure, 2009, 11, 3-5.	7.1	7
148	Cellular Mechanisms for Diastolic Dysfunction in the Human Heart. Current Pharmaceutical Biotechnology, 2012, 13, 2532-2538.	1.6	7
149	CrossTalk opposing view: The late sodium current is not an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction). Journal of Physiology, 2014, 592, 415-417.	2.9	7
150	Normal resting pulmonary artery wedge pressure: a diagnostic trap for heart failure with preserved ejection fraction. European Journal of Heart Failure, 2015, 17, 132-134.	7.1	7
151	p47phox-Dependent Reactive Oxygen Species Stimulate Nuclear Translocation of the FoxO1 Transcription Factor During Metabolic Inhibition in Cardiomyoblasts. Cell Biochemistry and Biophysics, 2018, 76, 401-410.	1.8	7
152	Failure of myocardial inactivation: a clinical assessment in the hypertrophied heart. , 1992, 87 Suppl 2, 145-161.		5
153	Turning the Retrospectroscope on Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2016, 22, 1023-1027.	1.7	4
154	Ancient Gunpowder and Novel Insights Team Up Against Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2015, 66, 1683-1686.	2.8	3
155	Adhesion Molecules in Early Adulthood Predict HeartÂFailure With Preserved Ejection Fraction at Older Age. Journal of the American College of Cardiology, 2020, 75, 2166-2168.	2.8	3
156	Response to Letter Regarding Article, "Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension― Circulation, 2008, 117, .	1.6	2
157	Increased nitrosative/oxidative stress lowers myocardial protein kinase G activity in heart failure with preserved ejection fraction. BMC Pharmacology & Toxicology, 2013, 14, .	2.4	2
158	Racial Tension in Hypertension. JACC: Heart Failure, 2017, 5, 166-168.	4.1	1
159	Diastole Tracks Cardiometabolic Risk. JACC: Heart Failure, 2018, 6, 326-328.	4.1	1
160	Failure of Inactivation of Hypertrophied Myocardium: A Cause of Impaired Left Ventricular Filling in Hypertrophic Cardiomyopathy and Aortic Stenosis. , 1987, , 291-304.		1
161	Invasive Evaluation of Diastolic Left Ventricular Dysfunction. , 2008, , 137-147.		1
162	Comparative Effects of Ischemia and Hypoxemia on Left Ventricular Diastolic Function in Humans. ,		1

1994, , 303-321.

#	Article	IF	CITATIONS
163	Response to Letter Regarding Article, "Peripartum Cardiomyopathy as a Part of Familial Dilated Cardiomyopathy― Circulation, 2011, 123, .	1.6	0
164	Clinical Cardiology: Current Practice GuidelinesKatritsisDemosthenes G.GershBernard J.CammA. John, eds. 1171 pages. Oxford, UK: Oxford University Press, 2013. ISBN-10: 0521867126. ISBN-13: 978-0521867122. pages. \$115.00. ISBN: 978-0-19-968528-8. Circulation, 2014, 129, 1171-1172.	23106	0
165	Alterations in Ventricular Function. , 2020, , 151-165.e3.		0
166	The Role of Nitric Oxide in the Failing Heart. Developments in Cardiovascular Medicine, 2001, , 35-48.	0.1	0
167	From hemodynamic principles to clinical management. Developments in Cardiovascular Medicine, 1991, , 1-20.	0.1	0